THEM6

Across TCGA pan-cancer cohorts, THEM6 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated THEM6 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher THEM6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated THEM6 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where THEM6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.839	0.548	.001	42	view →
GBM	DFS	Median	All	0.797	0.638	.005	19	view →
PDAC	OS	Quartile	III,IV	0.977	0.354	.011	13	view →
LSCC	DFS	Tertile	II,III,IV	0.935	0.709	.011	8	view →
LUAD	DFS	Quartile	All	0.503	0.926	.006	7	view →
HNSC	OS	Quartile	II,III,IV	0.882	0.578	.003	6	view →
UCEC	DFS	Quartile	All	0.850	1.000	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

THEM6–CCRCC (DFS)

Open the CCRCC breakdown →